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Abstract
Background: The aim of this study was to determine whether early tumor shrinkage (ETS) at 6 weeks after
treatment correlates with progression-free survival (PFS) and overall survival (OS) in advanced biliary tract cancer
(BTC) patients receiving gemcitabine plus oxaliplatin (GEMOX), with or without erlotinib.
Methods: This was a multicenter, open label, randomized, phase III trial of 103 BTC patients (ClinicalTrials.gov
Identifier; NCT01149122, and Rigistration date; January, 7, 2010), comparing GEMOX with GEMOX plus erlotinib.
Tumor shrinkage was expressed as a relative decrease compared to baseline and was dichotomized according to a
previously reported cutoff value of 10 %.
Results: Fifty-four patients (52.4 %) received GEMOX and 49 patients (47.6 %) received GEMOX plus erlotinib. The
latter achieved a better overall response rate (RR) (40.8 % vs. 18.6 %, p = 0.02) and showed ETS more frequently
(63.2 % vs. 40.7 %, p = 0.03). ETS was significantly correlated with the overall RR (correlation coefficient, 0.53; p < 0.01). The
median PFS and OS did not differ according to erlotinib administration. However, the median PFS (7.3 vs. 2.1 months,
p < 0.01) and OS (10.7 vs. 5.8 months, p < 0.01) were significantly longer amongst patients with ETS at 6 weeks after
treatment, irrespective of erlotinib administration. In patients with wild-type KRAS who were treated with GEMOX plus
erlotinib, ETS was a significant prognostic factor for PFS (p < 0.01).
Conclusions: ETS might predict PFS and OS in BTC patients treated with GEMOX with or without erlotinib. Additionally,
ETS may be an indication for adding erlotinib to chemotherapy for BTC patients wild-type KRAS. These findings need to
be prospectively validated.
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Background
Biliary tract cancers (BTCs), including cholangiocarci-
noma and gallbladder cancer, are relatively common in
South Korea [1]. Because of the non-specific symptoms
associated with these malignancies, more than 75 % of
cases are unresectable as they are diagnosed an advanced
disease stage. Moreover, even after complete resection,
many patients experience disease recurrence. Patients
with advanced or recurrent BTCs can be considered for
palliative chemotherapy [2, 3]. Combination chemother-
apy with gemcitabine and a platinum-based agent is
regarded as a standard first-line chemotherapy regimen
for advanced BTC, further to the results of previous
randomized phase II and III trials (ABC01 and 02)
[4, 5]. More recently, we conducted a phase III trial
(NCT01149122) of gemcitabine and oxaliplatin (GEMOX)
with or without erlotinib, a tyrosine kinase inhibitor that
blocks epidermal growth factor receptor (EGFR) signaling.
We found that the median progression-free survival (PFS)
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was 4.2 months in the GEMOX group and 5.8 months in
the GEMOX plus erlotinib group [6]. These findings sug-
gested that the addition of erlotinib to GEMOX might be
considered as one of treatment options for BTC patients,
although the difference in PFS between the groups was not
significant.
Identifying patients who will derive the most benefit
from treatment with a targeted agent is an important
goal [7]. It is clear from the history of using anti-EGFR
monoclonal antibodies (mAbs), including cetuximab, to
treat cancer that not all patients benefit from these
agents [8–10]. For example, colorectal cancer (CRC) pa-
tients with mutant KRAS tumors will not respond to or
derive long-term benefit from treatment with anti-EGFR
mAbs. However, no clinical characteristics or molecular
biomarkers are currently available to identify subgroups
of BTC patients who might survive longer if treated with
a targeted agent. Previously, we evaluated the roles of
EGFR, KRAS, and PIK3CA as biomarkers in patients
with advanced BTC who received GEMOX with or with-
out erlotinib, and found that KRAS status might be a
predictive marker of response to erlotinib, but not of
survival. Thus, further predictive markers of response
and survival benefit after chemotherapy are urgently
needed to facilitate the rational and effective use of
drugs in cases of advanced BTC.
Rapid tumor shrinkage has been shown to be a surro-
gate marker of tumor EGFR dependency and conse-
quently of cetuximab sensitivity, and several studies have
reported that early tumor shrinkage (ETS) is associated
with better long-term survival in metastatic CRC pa-
tients treated with anti-EGFR therapies [8, 11–13].
These findings also suggest that ETS may be a useful
surrogate marker for making on-treatment decisions in-
cluding continuation or discontinuation of therapy in
daily practice. We hypothesized that adding erlotinib to
chemotherapy could improve early tumor response in
EGFR-positive BTC tumors. To investigate this hypoth-
esis, we retrospectively analyzed clinical data from our
previous randomized trial [6] and evaluated the predict-
ive value of ETS for long-term outcomes in advanced




The eligibility criteria and design of this study have been
previously described [6]. Briefly, this was an open-label,
randomized, phase III trial, in which 268 patients with
advanced BTCs were randomly assigned to receive either
erlotinib plus GEMOX (135 patients) or GEMOX alone
(133 patients) as first-line treatment. All patients pro-
vided written informed consent according to institu-
tional guidelines, and the study was approved by the
Institutional Review Board. Tumor response was evalu-
ated every 6 weeks using computed tomography (CT)
and was assessed by the local investigators according to
the Response Evaluation Criteria in Solid Tumors, ver-
sion 1.0. A total of 103 patients were available for the
evaluation of ETS 6 weeks after treatment as well as
tumor KRAS mutation status (Fig. 1). Tumor shrinkage
was expressed as a relative decrease compared to base-
line and was categorized according to a previously re-
ported cutoff value (10 %) [8, 12].
Definition of ETS
Successive measurements of the target lesion were avail-
able for analysis. Changes in tumor size were expressed
as a relative change of the sum of the longest diameter
(LD) of the target lesions. ETS was calculated as the ra-
tio of the sum of tumor LDs before treatment and
6 weeks after treatment. Patients who showed a reduc-
tion in tumor size of at least 10 % 6 weeks after treat-
ment were considered to have achieved ETS.
DNA Extraction and Mutation Analysis of KRAS
DNA was extracted from five 10-μm-thick formalin-
fixed paraffin embedded sections containing a represen-
tative portion of each tumor block, using the QIAamp
DNA Mini kit (Qiagen, Hilden, Germany). A pathologist
(K.T.J) reviewed each slide and verified that more than
50 % of the tissue consisted of malignant cells.
Peptide nucleic acid (PNA)-locked nucleic acid poly-
merase chain reaction (PCR) clamping was carried out
using the PNA-Clamp™ KRAS Detection kit (Panagene,
Inc., Daejeon, Korea), as described previously. Briefly,
the reaction mixture contained 10–25 ng template
DNA, primer and PNA probe set, and SYBR Green PCR
master mix in a total volume of 20 μl. All necessary re-
agents were included in the kit. Real-time PCR reactions
of PNA-mediated PCR clamping were performed using a
CFX 96 system (Bio-Rad, USA). PCR cycling conditions
were a 5-min hold at 94 °C, followed by 40 cycles of 94 °C
for 30 s, 70 °C for 20 s, 63 °C for 30 s, and 72 °C for 30 s.
This method allowed 7 different mutations in exon 2 of
the KRAS gene to be detected.
Statistical analysis
Descriptive statistics were reported as proportions and
median. The correlation between ETS and overall tumor
response was evaluated using Spearman’s correlation.
PFS was defined as the time from date of first study
treatment to date of first documented disease progres-
sion or death. Overall survival (OS) was calculated from
the first study treatment until death. PFS and OS were
evaluated according to treatment and achievement of
ETS, and differences were analyzed using the Kaplan-
Meier method and stratified log-rank test. Additionally,
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for a subgroup of patients with wild-type KRAS tumors,
Kaplan-Meier plots were constructed for PFS according
to treatment and achievement of ETS and were com-
pared using the log-rank test. Hazard ratios (HRs) were
estimated using the Cox proportional hazards model.
P < 0.05 was considered significant.
Ethics statement
The Ethics Committee at Samsung Medical Center ap-
proved the study in accordance with the Declaration of
Helsinki. All individuals gave written informed consent
for participation in the study.
Results
Patient characteristics
This analysis included 103 patients who received GEMOX
alone (n = 54) or GEMOX plus erlotinib (n = 49) as first-
line treatment for advanced BTCs. Patient characteristics
according to the treatment received are summarized in
Table 1. The baseline patient characteristics did not differ
significantly between the treatment groups (Table 1), with
the exception of predominantly metastatic disease that oc-
curred significantly more frequently in the GEMOX group
than in the GEMOX plus erlotinib group (92.6 % vs.
63.3 %, p = 0.04).
ETS and tumor response
A total of 53 patients (51.4 %) showed ETS 6 weeks after
treatment, 22 (40.7 %) in the GEMOX group and 31
(63.2 %) in the GEMOX plus erlotinib group (p = 0.03)
(Table 2). Of the 54 patients who received GEMOX
alone, 3 patients had achieved objective response (5.6 %)
Fig. 1 CONSORT flow diagram
Table 1 Characteristics of 103 advanced biliary tract cancer








Median 62 (45–75) 59 (39–75)
Sex
Male 35 (64.8 %) 33 (67.3 %)
Female 19 (35.2 %) 16 (32.7 %)
Primary site
Cholangiocarcinoma 38 (70.4 %) 38 (77.6 %)
Gallbladder (GB) 16 (29.6 %) 11 (22.4 %)
Differentiation
Well/Moderate 33 (61.1 %) 26 (53.1 %)
Poorly 21 (38.9 %) 23 (46.9 %)
Disease status
Recurrent 4 (7.4 %) 18 (36.7 %)
Primarily metastatic 50 (92.6 %) 31 (63.3 %)
Liver only metastasis
Yes 10 (18.5 %) 8 (16.3 %)
No 44 (81.5 %) 41 (83.7 %)
Number of metastatic sites
1 43 (79.6 %) 41 (83.7 %)
2 ≤ 11 (20.4 %) 8 (16.3)
KRAS status
Mutant 3 (5.6 %) 5 (10.2 %)
Wild 51 (94.4 %) 44 (89.8 %)
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at the first response evaluation 6 weeks after treatment
and 10 patients had achieved overall response (18.6 %).
The patients receiving GEMOX plus erlotinib showed a
significantly better objective response rate (14/49, 30.6 %,
p < 0.01) and overall response rate (20/49, 40.8 %, p =
0.02) during the same 6-week follow up. Additionally, ETS
was significantly correlated with overall response (correl-
ation coefficient, 0.529; p < 0.01) (Table 3).
PFS and OS according to ETS
There was no statistically significant difference in either
PFS or OS (log-rank test, p = 0.64 and 0.95, respectively)
between the GEMOX alone and GEMOX with erlotinib
groups (Fig. 2). In the GEMOX group, the median PFS
was 2.5 months (95 % confidence interval [CI], 1.7–
3.2 months) for patients without ETS and 5.4 months
(95 % CI, 2.0–8.9 months) for patients with ETS (p = 0.03,
Table 4). There was also a significant difference in OS
between patients with and without ETS (9.5 months vs.
4.8 months, p = 0.03). In the GEMOX plus erlotinib
group, the median PFS was 1.3 months (95 % CI, 1.0–
1.6 months) for patients without ETS and 8.3 months
(95 % CI, 5.7–11.0) for patients with ETS (p < 0.01,
Table 4). OS was also significantly different between pa-
tients with and without ETS (11.4 months vs. 6.4 months,
p < 0.01). The median PFS (7.3 vs. 2.1 months, p < 0.01)
and OS (10.7 vs. 5.8 months, p < 0.01) were significantly
longer amongst patients with ETS at 6 weeks, irrespective
of the treatment received (Fig. 3).
Impact of ETS and erlotinib treatment in patients with
wild-type KRAS tumors
In a subgroup analysis of 95 patients with wild-type
KRAS tumors, the median PFS was not significantly dif-
ferent between treatment groups (2.9 months for the
GEMOX group vs. 6.1 months for the GEMOX plus
erlotinib group, p = 0.36), but this was significantly lon-
ger in patients with ETS than in those without ETS
(6.8 months for ETS vs. 1.5 months for no ETS, p < 0.01)
(Fig. 4). ETS was more strongly associated with PFS in
patients with wild-type KRAS tumors who were treated
with erlotinib (8.3 months for ETS vs. 1.2 months for no
ETS, p < 0.01) (Fig. 5).
Discussion
This analysis of the previously reported GEMOX and er-
lotinib trial for BTC demonstrated that ETS 6 weeks
after first-line GEMOX treatment either with or without
erlotinib correlates with PFS and OS. The median PFS
and OS for patients with ETS were significantly longer
than those for patients without ETS, irrespective of the
treatment regimen (7.3 vs. 2.1 months, p < 0.01, and 10.7
vs. 5.8 months, p < 0.01, respectively). Although a strong
association between ETS and long-term outcome has
been reported in patients with metastatic CRC [8, 11,
12, 14], this is the first study to demonstrate such a
relationship in BTC patients.
Selecting patients who will benefit from anti-cancer
therapy is an important goal. Biomarkers of response
and long-term survival benefit from palliative chemo-
therapy are urgently needed for various cancer types for
the rational and effective use of drugs. In our phase III
trial (NCT01149122) of GEMOX with or without erloti-
nib, performance status, primary tumor site, and metas-
tasis limited to the liver were assessed as potential
prognostic factors for long PFS irrespective of the treat-
ment regimen [6]. However, these factors are already
included in the patients’ baseline characteristics and can-
not help guide treatment decisions, including whether to
continue or discontinue therapy. ETS is a known prognos-
tic parameter for the outcome of metastatic CRC patients
with wild-type KRAS tumors receiving cetuximab [8, 11],
and a number of studies have demonstrated a relationship
between ETS and clinical outcomes after cetuximab ther-
apy for pretreated metastatic CRC [8, 11, 13–15]. Thus,
early changes in response to treatment could help identify
Table 2 Overall response rate and early tumor shrinkage
6 weeks after treatment








10 %≤ 53 (51.4 %) 22 40.7 %) 31 (63.2 %) 0.03
Response at 6 weeks
(RECIST)
18 (17.4 %) 3 (5.6 %) 15 (30.6 %) 0.00
Complete response 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Partial response 18 (17.4 %) 3 (5.6 %) 15 (30.6 %)
Stable disease 72 (69.9 %) 44 (81.5%) 28 (57.1)
Progressive disease 13 (12.6 %) 7 (13.0 %) 6 (12.2 %)
Overall response
(RECIST)
30 (29.0 %) 10 (18.6%) 20 (40.8 %) 0.02
Complete response 1 (0.9 %) 1 (1.9 %) 0 (0.0 %)
Partial response 29 (28.1 %) 9 (16.7 %) 20 (40.8 %)
Stable disease 50 (48.5 %) 32 (59.3 %) 18 (36.7 %)
Progressive disease 23 (22.3 %) 12 (22.2 %) 11 (22.4 %)
Table 3 Correlation between early tumor shrinkage 6 weeks
after treatment and overall response
Overall response Sum
Response Non-response
Early tumor shrinkage Yes 17 6 23
No 13 67 80
Sum 30 73 103
(Correlation coefficient: 0.529, p < 0.001)
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patients who would benefit from a continuation of ther-
apy. To date, there have been no effective surrogate bio-
markers for predicting response and survival outcome
after treatment in advanced BTC patients. Our findings
suggest that ETS at 6 weeks might to be a good predictive
marker for long-term outcomes in advanced BTC and
could guide on-treatment decisions including continu-
ation or discontinuation of therapy, although further con-
firmation by a prospective trial is needed.
We used a cutoff value of a 10 % decrease in tumor
size at 6 weeks as the criterion for ETS. This value was
previously used as a cutoff to predict improved outcome
in Choi’s criteria for gastrointestinal stromal tumors
treated with imatinib and metastatic CRC treated with
cetuximab [8, 12, 16]. The significance of this apparently
rather small decrease might be related to the number of
cancer cells actually eradicated by treatment; in a spher-
ical tumor, 10 % shrinkage would indicate that almost
30 % of cells have been killed [17, 18].
There is growing evidence that the EGFR pathway is a
potential therapeutic target in BTC [19, 20]. Although
KRAS mutations are associated with less efficient EGFR-
directed targeted therapy in various cancer types, it is
not yet known if the same is true in BTC [21, 22]. Previ-
ously, we assessed whether the KRAS status could act as
a predictive biomarker in patients with advanced BTC
who received erlotinib, and this suggested that the KRAS
mutation might be a predictor of resistance to small-
molecule EGFR inhibitors. In present analysis, GEMOX
plus erlotinib group included only 5 patients with KRAS
mutant tumor. Thus, we could not evaluate the role of
KRAS status as a biomarker to erlotinb. Instead, we
found a strong association between ETS and long-term
outcome in patients with wild-type KRAS BTC tumors
Fig. 2 Progression-free survival (PFS) (a) and overall survival (OS) (b) of patients treated with gemcitabine and oxaliplatin (GEMOX) alone or
GEMOX with erlotinib (GEMOXT)
Table 4 Kaplan-Meier median progression-free survival (PFS)
and overall survival (OS) estimates for patients with and without
early tumor shrinkage
Early tumor shrinkage at
6 weeks
p-value
<10 % ≥10 %
GEMOX PFS (months)
median (95 % CI)




median (95 % CI)
1.3 (1.0-1.6) 8.3 (5.7-11.0) 0.00
Overall PFS (months)
median (95 % CI)
2.1 (0.9-3.3) 7.3 (5.6-8.9) 0.00
Early tumor shrinkage at
6 weeks
p-value
<10 % ≥10 %
GEMOX OS (months)
median (95 % CI)




median (95 % CI)
6.4 (3.1-9.6) 11.4 (7.6-15.2) 0.00
Overall OS (months)
median (95 % CI)
5.8 (3.0-8.5) 10.7 (8.9-12.6) 0.00
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Fig. 3 Progression-free survival (PFS) (a) and overall survival (OS) (b) for patients with or without early tumor shrinkage (ETS) 6 weeks
after treatment
Fig. 4 Progression-free survival (PFS) according to treatment with gemcitabine and oxaliplatin (GEMOX) or GEMOX with erlotinib (GEMOXT) (a)
and early tumor shrinkage (ETS) 6 weeks after treatment (b) in patients with wild-type KRAS tumors
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who were treated with first-line chemotherapy plus
erlotinib. This suggests that ETS might help identify
a distinct subgroup of advanced BTC patients with
wild-type KRAS tumors who could benefit from erlo-
tinib treatment.
This study had several limitations. First, this analysis
was available in only 103 out of 268 patients who had
been enrolled in our phase III trial. Moreover, the sub-
groups were relatively too small. Small sample size and
selection bias of the current study may make definitive
conclusions difficult. Second, we retrospectively evalu-
ated only one time point (the follow-up at 6 weeks),
which was defined in the study protocol. We are not
sure if this time point is optimal for measuring early
tumor changes. Therefore, validation in a prospective
trial with ETS measured at various time points is
needed. Third, because it is well known that extensive
desmoplasia and surrounding inflammation in BTC
make it difficult to measure tumor responses accurately
using conventional methods, new technology for evalu-
ating tumor bioactivity such as PET-CT may allow the
treatment effect to be measured more precisely.
The rarity of BTC hinders clinicians from conducting
definitive trials and from producing rigorous scientific
data. Thus, coordination of trials among institutions and
cooperative groups, both nationally and internationally,
will be the key to improving treatment outcomes in
BTCs.
Conclusion
ETS 6 weeks after treatment is a possible predictive
marker of PFS and OS in advanced BTC. Further to our
analysis, we also propose that ETS may help determine
whether the addition of erlotinib to chemotherapy would
be beneficial to BTC patients with wild-type KRAS tu-
mors. These findings need to be prospectively validated.
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